Pharmacokinetics and biodistribution of genetically engineered antibodies

Surinder K. Batra, Maneesh Jain, Uwe A. Wittel, Subhash C. Chauhan, David Colcher

Research output: Contribution to journalReview articlepeer-review

170 Scopus citations


The engineering of monoclonal antibodies has created a new generation of pharmaceuticals with the desired pharmacokinetics and biodistribution properties. For radioimmunotherapy and radioscintigraphy, optimum tumor targeting can be achieved using engineered constructs that provide high antigen affinity and specificity, effective tumor penetration, circulation properties that allow high tumor uptake with acceptable doses to the normal tissues, and fast clearance allowing low background. Recent advances have made possible the development of antibodies with these properties.

Original languageEnglish (US)
Pages (from-to)603-608
Number of pages6
JournalCurrent Opinion in Biotechnology
Issue number6
StatePublished - Dec 1 2002

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering


Dive into the research topics of 'Pharmacokinetics and biodistribution of genetically engineered antibodies'. Together they form a unique fingerprint.

Cite this